Phaseline

Targets › PD-1

PD-1: drug programs, companies and trials

5 programs from 5 companies in 29 trials: 23 Phase 2, 6 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: the race on PD-1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yongxu JiaIparomlimab and Tuvonralimab Injection (QL1706)
CTLA-4 and PD-1 dual checkpoint inhibitor
CTLA4, PD-1Phase 2Gastroesophageal Junction AdenocarcinomaSep 2027
Qilu Hospital of Shandong UniversityIparomlimab and Tuvonralimab (QL1706)
Dual CTLA-4 and PD-1 inhibitor
CTLA4, PD-1Phase 2HER2 NegativeOct 2027
Tianjin Medical University Cancer Institute and HospitalIparomlimab/Tuvonralimab
CTLA-4 and PD-1 inhibitor combination
CTLA4, PD-1Phase 2HCC - Hepatocellular CarcinomaAug 2028
West China HospitalIvonescimab
PD-1 and CTLA-4 dual inhibitor
PD-1, CTLA4Phase 2Head and Neck Squamous Cell CarcinomaDec 2028
Revolution MedicinesIvonescimab
PD-1 and CTLA-4 dual antagonist
PD-1, CTLA4Phase 1Advanced Solid Tumors; Stomach Cancer Stage IV; Small Cell Lung Cancer; Recurrent or Metastatic Nasopharyngeal Carcinoma …May 2029

Conditions

Non-Small Cell Lung Cancer (4) Advanced Solid Tumors (1) Stomach Cancer Stage IV (1) Small Cell Lung Cancer (1) Recurrent or Metastatic Nasopharyngeal Carcinoma (1) Rectal Cancer (1) Endometrial Cancer (1) Cutaneous Angiosarcoma (1) Pancreatic Cancer (1) Biliary Tract Cancer (1) Metastatic Endocrine Refractory (1) TNBC (1)

Modalities

mixed (3), antibody (2)

Companies

Revolution Medicines (1) Yongxu Jia (1) Qilu Hospital of Shandong University (1) West China Hospital (1) Tianjin Medical University Cancer Institute and Hospital (1)

Related targets

CTLA4 (5)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.